交易中 04-01 11:21:05 美东时间
+0.340
+1.03%
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Axogen业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - Q4营收5,990万美元,同比增长21.3% - 全年营收2.252亿美元,同比增长20.2% - 三个核心市场均实现双位数增长 **盈利能力:** - Q4毛利润4,440万美元,毛利率74.1%(同比下降2个百分点) - 全年毛利润1.674亿美元,毛利率74.3%(同比下降1.5个百分点) - 毛利润受FDA BLA批准相关的一次性成本影响,Q4影响190万美元,全年影响占比0.9% **净利润:** - Q4净亏损1,320万美元(每股亏损0.
02-25 12:24
今日重点评级关注:花旗:维持Telix Pharmaceuticals"买入"评级,目标价从22美元升至22.5美元;摩根士丹利:维持Vir Biotechnology"超配"评级,目标价从20美元升至24美元
02-25 11:03
Axogen shares are trading lower after the company reported worse-than-expected ...
02-25 03:27
Gainers Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 65.0% to $12.26...
02-24 20:05
Axogen (NASDAQ:AXGN) sees FY2026 sales of $265.700 million vs $259.499 million analyst estimate.
02-24 20:04
Axogen (NASDAQ:AXGN) released its Q4 earnings on Tuesday, February 24, 2026 at ...
02-24 20:04
Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.08 by 12.5 percent. This is unchanged from the same period last year. The company reported quarterly
02-24 20:03
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
今日重点评级关注:Stephens & Co.:维持圣玛丽石油勘测"超配"评级,目标价从48美元升至49美元;花旗:维持IDEAYA Biosciences"买入"评级,目标价从64美元升至65美元
02-20 15:57
Wells Fargo analyst Larry Biegelsen initiates coverage on Axogen (NASDAQ:AXGN) with a Overweight rating and announces Price Target of $40.
02-19 21:20